Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes in Nulliparous Women After Assisted Reproductive Technology (APPART)

What this Trial Is About

Researchers are studying nulliparous pregnant women who have conceived through Assisted Reproductive Technology (ART) to evaluate if aspirin can help prevent preterm preeclampsia and related pregnancy complications. This group is considered at higher risk for preeclampsia and perinatal issues, with a current rate of preeclampsia up to 10%. The study aims to determine if aspirin given during pregnancy reduces these risks in this specific population. Participants are randomly assigned to receive either a daily oral dose of 150 mg low-dose aspirin or a matching placebo. Treatment starts between 9 and 14 weeks of pregnancy and continues until 35 weeks and 6 days of gestation or until labor begins. The study compares outcomes between these two groups to assess the effects of aspirin. During the trial, participants will be monitored for the development of preterm preeclampsia before 37 weeks of gestation and other pregnancy outcomes such as preterm birth, cesarean delivery, postpartum hemorrhage, placental abruption, and neonatal adverse events. The study will last up to 9 months, covering the pregnancy period, with data collected to evaluate the aspirin's impact on these health measures.

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology